Immunocore Holdings plc (NASDAQ:IMCR) Receives $79.82 Average PT from Analysts

Immunocore Holdings plc (NASDAQ:IMCR) has been given an average rating of “Moderate Buy” by the fourteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $75.17.

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a report on Monday, September 9th. Oppenheimer reiterated an “outperform” rating and issued a $89.00 price objective (up previously from $87.00) on shares of Immunocore in a research report on Friday, August 9th. JPMorgan Chase & Co. decreased their target price on shares of Immunocore from $70.00 to $66.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 10th. Needham & Company LLC cut their price target on shares of Immunocore from $81.00 to $78.00 and set a “buy” rating for the company in a report on Tuesday, September 17th. Finally, UBS Group began coverage on shares of Immunocore in a report on Thursday. They set a “sell” rating and a $24.00 price objective on the stock.

Immunocore Stock Performance

Shares of IMCR stock opened at $32.50 on Tuesday. The stock’s 50-day moving average price is $33.48 and its 200 day moving average price is $41.40. The company has a quick ratio of 5.15, a current ratio of 5.17 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $1.63 billion, a PE ratio of -26.64 and a beta of 0.72. Immunocore has a 52-week low of $29.72 and a 52-week high of $76.98.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.25. The company had revenue of $75.40 million for the quarter, compared to analysts’ expectations of $74.58 million. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. Immunocore’s revenue was up 26.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.37) EPS. As a group, equities research analysts forecast that Immunocore will post -1.67 EPS for the current year.

Institutional Investors Weigh In On Immunocore

A number of large investors have recently bought and sold shares of the stock. Primecap Management Co. CA raised its holdings in shares of Immunocore by 3,841.6% in the second quarter. Primecap Management Co. CA now owns 1,951,070 shares of the company’s stock worth $66,122,000 after acquiring an additional 1,901,570 shares during the last quarter. Armistice Capital LLC raised its stake in Immunocore by 495.1% in the 2nd quarter. Armistice Capital LLC now owns 976,000 shares of the company’s stock valued at $33,077,000 after purchasing an additional 812,000 shares during the last quarter. Fiera Capital Corp lifted its holdings in Immunocore by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 875,593 shares of the company’s stock valued at $29,674,000 after purchasing an additional 9,181 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Immunocore by 14.5% during the 2nd quarter. Renaissance Technologies LLC now owns 646,920 shares of the company’s stock worth $21,924,000 after purchasing an additional 82,120 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Immunocore by 124.4% during the second quarter. Millennium Management LLC now owns 600,954 shares of the company’s stock worth $20,366,000 after buying an additional 333,167 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.